Hefei Heyuan Pharmaceutical Technology

Hefei Heyuan Pharmaceutical Technology is a clinical-stage biotechnology company based in Hefei, China, specializing in the development of innovative cell therapies for hematological malignancies and solid tumors. The company focuses on Chimeric Antigen Receptor T-cell (CAR-T) and CAR-NK cell technologies, with a pipeline featuring both single and dual-target candidates. Its lead program, HY001, is a CD19-targeted CAR-T therapy currently undergoing clinical evaluation for B-cell malignancies. Hefei Heyuan leverages its proprietary cell engineering platforms to improve the efficacy and safety of immunotherapy, aiming to provide accessible and effective treatments for cancer patients. The company has established a GMP-compliant manufacturing facility to support its clinical trials and future commercialization efforts.